ExeVir logo.png
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
January 15, 2024 03:00 ET | ExeVir Bio
GHENT, Belgium, Jan. 15, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today...
ExeVir logo.png
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
June 28, 2023 03:09 ET | ExeVir Bio
Dengue is a mosquito-borne viral infection listed by WHO as top 10 threat for global health The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO) GHENT, Belgium, June...
ExeVir logo.png
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
March 13, 2023 05:00 ET | ExeVir Bio
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spikeFocus on protecting...
ExeVir logo.png
ExeVir Bio contracte un prêt d’amorçage-investissement de 25 millions d’euros auprès de la Banque européenne d’investissement
January 09, 2023 02:00 ET | ExeVir Bio
Financer le développement scientifique de traitements innovants contre le COVID-19 basés sur des nanocorps, visant à protéger des personnes immunodéprimées à haut risque L’entreprise développe des...
ExeVir Bio ontvangt
ExeVir Bio ontvangt 25 miljoen euro financiering met durfkapitaal van de Europese Investeringsbank
January 09, 2023 02:00 ET | ExeVir Bio
Financiering voor de verdere wetenschappelijke ontwikkeling van innovatieve COVID-19-behandelingen met nanobody’s voor de bescherming van hoog risicogroepen met verminderde immuniteit Het bedrijf...
ExeVir logo.png
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
January 09, 2023 02:00 ET | ExeVir Bio
Financing to advance the scientific development of innovative COVID-19 nanobody treatments focused on protecting high-risk immunocompromised individuals Company developing highly potent antibodies...